82_FR_19151 82 FR 19073 - Government-Owned Inventions; Availability for Licensing

82 FR 19073 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 78 (April 25, 2017)

Page Range19073-19073
FR Document2017-08351

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 78 (Tuesday, April 25, 2017) 
[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Page 19073]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-08351]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
[email protected]. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

A Second CD4-Binding Region of HIV-1 gp120 Critical for Viral 
Infectivity: New Methods for Treatment and Vaccine Development

    Description of Technology: It is believed that immunization with an 
effective immunogen based on the HIV-1 envelope glycoprotein can elicit 
a neutralizing antibody response, which may be protective against HIV-1 
infection. NIAID researchers have discovered a new critical component 
of the CD4-binding site in gp120, named CD4-BS2, which is exclusively 
formed in the trimeric envelope conformation. It was further found that 
this newly recognized region is critical for the progression of the 
fusogenic mechanism that leads to HIV-1 entry and infection of the 
cells. This discovery may lead to new methods of treatment, for 
treating HIV-1, as well as to the production of new vaccine immunogens.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications: New target for HIV therapeutic 
and vaccine development.
    Competitive Advantages: A new molecular target discovered in this 
invention may facilitate the development of next-generation HIV 
therapeutics and vaccines.
    Development Stage: Proof-of-concept studies demonstrate that CD4 
binding to CD4-BD2 is critical for triggering gp120 conformational 
changes that enable coreceptor binding and HIV-1 infectivity. Animal 
studies are ongoing.
    Inventors: Paolo Lusso, NIAID, NIH; and Qingbo Liu, NIAID, NIH.
    Publications: Liu, Qingbo, et al. ``Quaternary contact in the 
initial interaction of CD4 with the HIV-1 envelope trimer.'' Nature 
Structural & Molecular Biology (2017).
    Intellectual Property: HHS Reference No. E-230-2015/0--U.S. Patent 
Application No. 62/292,750 filed 02/08/2016; PCT Application No. PCT/
US2017/017038 filed 02/08/2017.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop HIV-1 vaccines and/or 
inhibitors that target the newly recognized region. For collaboration 
opportunities, please contact Chris Kornak, 240-627-3705, 
[email protected].

    Dated: April 10, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-08351 Filed 4-24-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices 19073 the authority for ICCVAM involvement DEPARTMENT OF HEALTH AND development and evaluation under a in activities relevant to the development HUMAN SERVICES research collaboration. of alternative test methods. ICCVAM Potential Commercial Applications: acts to ensure that new and revised test National Institutes of Health New target for HIV therapeutic and methods are validated to meet the needs vaccine development. Government-Owned Inventions; Competitive Advantages: A new of federal agencies, increase the Availability for Licensing molecular target discovered in this efficiency and effectiveness of federal agency test method review, and invention may facilitate the AGENCY: National Institutes of Health, optimize utilization of scientific development of next-generation HIV HHS. expertise outside the federal therapeutics and vaccines. ACTION: Notice. Development Stage: Proof-of-concept Government. Additional information studies demonstrate that CD4 binding to about ICCVAM can be found at http:// SUMMARY: The inventions listed below CD4–BD2 is critical for triggering gp120 ntp.niehs.nih.gov/go/iccvam. are owned by an agency of the U.S. conformational changes that enable NICEATM administers ICCVAM, Government and are available for coreceptor binding and HIV–1 provides scientific and operational licensing to achieve expeditious infectivity. Animal studies are ongoing. support for ICCVAM-related activities, commercialization of results of Inventors: Paolo Lusso, NIAID, NIH; and conducts and publishes analyses federally-funded research and and Qingbo Liu, NIAID, NIH. and evaluations of data from new, development. Foreign patent Publications: Liu, Qingbo, et al. applications are filed on selected ‘‘Quaternary contact in the initial revised, and alternative testing inventions to extend market coverage interaction of CD4 with the HIV–1 approaches. NICEATM and ICCVAM for companies and may also be available envelope trimer.’’ Nature Structural & work collaboratively to evaluate new for licensing. and improved testing approaches Molecular Biology (2017). applicable to the needs of U.S. federal FOR FURTHER INFORMATION CONTACT: Intellectual Property: HHS Reference agencies. NICEATM and ICCVAM Chris Kornak, 240–627–3705, No. E–230–2015/0—U.S. Patent chris.kornak@nih.gov. Licensing Application No. 62/292,750 filed 02/08/ welcome the public nomination of new, information and copies of the U.S. 2016; PCT Application No. PCT/ revised, and alternative testing patent applications listed below may be US2017/017038 filed 02/08/2017. approaches for validation studies and Licensing Contact: Chris Kornak, 240– obtained by communicating with the technical evaluations. Additional 627–3705, chris.kornak@nih.gov. indicated licensing contact at the information about NICEATM can be Technology Transfer and Intellectual Collaborative Research Opportunity: found at http://ntp.niehs.nih.gov/go/ Property Office, National Institute of The Technology Transfer and niceatm. Allergy and Infectious Diseases, 5601 Intellectual Property Office (TTIPO) is Dated: April 13, 2017. Fishers Lane, Rockville, MD 20852; tel. seeking parties interested in John R. Bucher, 301–496–2644. A signed Confidential collaborative research to further co- Disclosure Agreement will be required develop HIV–1 vaccines and/or Associate Director, National Toxicology Program. to receive copies of unpublished patent inhibitors that target the newly applications. recognized region. For collaboration [FR Doc. 2017–08354 Filed 4–24–17; 8:45 am] SUPPLEMENTARY INFORMATION: opportunities, please contact Chris BILLING CODE 4140–01–P Kornak, 240–627–3705, chris.kornak@ Technology description follows. nih.gov. A Second CD4-Binding Region of Dated: April 10, 2017. DEPARTMENT OF HEALTH AND HIV–1 gp120 Critical for Viral HUMAN SERVICES Suzanne Frisbie, Infectivity: New Methods for Treatment and Vaccine Development Deputy Director, Technology Transfer and National Institutes of Health Intellectual Property Office, National Institute Description of Technology: It is of Allergy and Infectious Diseases. National Cancer Institute; Cancellation believed that immunization with an [FR Doc. 2017–08351 Filed 4–24–17; 8:45 am] of Meeting effective immunogen based on the HIV– BILLING CODE 4140–01–P 1 envelope glycoprotein can elicit a Notice is hereby given of the neutralizing antibody response, which cancellation of the National Cancer may be protective against HIV–1 DEPARTMENT OF HEALTH AND Institute Special Emphasis Panel, May infection. NIAID researchers have HUMAN SERVICES 1, 2017, 8:00 a.m. to May 2, 2017, 1:00 discovered a new critical component of p.m., Hyatt Regency Bethesda, One the CD4-binding site in gp120, named National Institutes of Health Bethesda Metro Center, 7400 Wisconsin CD4–BS2, which is exclusively formed in the trimeric envelope conformation. National Institute on Aging; Notice of Avenue, Bethesda, MD 20814 which Closed Meeting was published in the Federal Register It was further found that this newly on March 22, 2017, 82 FR 54. recognized region is critical for the Pursuant to section 10(d) of the progression of the fusogenic mechanism Federal Advisory Committee Act, as This meeting is being amended to that leads to HIV–1 entry and infection amended (5 U.S.C. App.), notice is asabaliauskas on DSK3SPTVN1PROD with NOTICES cancel the meeting on May 1–2, 2017. of the cells. This discovery may lead to hereby given of the following meeting. Dated: April 20, 2017. new methods of treatment, for treating The meeting will be closed to the Melanie J. Pantoja, HIV–1, as well as to the production of public in accordance with the Program Analyst, Office of Federal Advisory new vaccine immunogens. provisions set forth in sections Committee Policy. This technology is available for 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., [FR Doc. 2017–08348 Filed 4–24–17; 8:45 am] licensing for commercial development as amended. The grant applications and in accordance with 35 U.S.C. 209 and 37 the discussions could disclose BILLING CODE 4140–01–P CFR part 404, as well as for further confidential trade secrets or commercial VerDate Sep<11>2014 17:42 Apr 24, 2017 Jkt 241001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\25APN1.SGM 25APN1


Document Created: 2017-04-25 02:18:24
Document Modified: 2017-04-25 02:18:24
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactChris Kornak, 240-627-3705, [email protected] Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 19073 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR